The influence of HPMC concentration on release of theophylline or hydrocortisone from extended release mini-tablets
Aug. 1, 2013, midnight
Faiezah A. A. Mohamed
James L. Ford
Ali R. Rajabi-Siahboomi
Remove from favorites
Add to favorites
Mini-tablets, compact dosage forms typically 2–3 mm in diameter, offer potential advantages for paediatric drug delivery. Extended-release (ER) oral dosage forms aim to provide controlled drug release for prolonged therapeutic action. Polymers like hypromellose (HPMC) are commonly used to create ER hydrophilic matrices.
Develop ER mini-tablets of various sizes for paediatric delivery and investigate the impact of HPMC concentration, tablet diameter, and drug solubility on the release rate.
Determine the solubility of hydrocortisone and theophylline. Formulate mini-tablets (2 and 3 mm) and tablets (4 and 7 mm) containing theophylline or hydrocortisone with HPMC (METHOCEL™ K15M) at different concentrations (30, 40, 50, and 60% w/w). Study the effects of tablet size, HPMC concentration, and drug solubility on release rate and tensile strength.
Results and Discussion:
Increasing HPMC content and tablet diameter significantly reduced the drug release rate from ER mini-tablets. Theophylline-containing tablets and mini-tablets exhibited faster drug dissolution than those with hydrocortisone, highlighting the influence of drug solubility on release from ER matrices. The results suggest that altering polymer content and mini-tablet diameter allows for different drug release profiles and doses, providing dose flexibility to meet paediatric requirements.
This study demonstrates the feasibility of producing ER mini-tablets to sustain drug release rates, offering dose flexibility for paediatric patients. Tailoring drug release rates can be achieved by adjusting mini-tablet size or HPMC levels without compromising tablet strength.